|
Portal - COVID-19 Patient Care Information - American Society of Clinical Oncology ASCO invited its members to submit questions about issues and challenges they see emerging while caring for individuals with cancer during the coronavirus pandemic. Currently, limited clinical cancer-specific data are available and information is evolving. The following information is based on evidence gathered through PubMed searches of the medical literature, a search of relevant websites with information on infectious diseases (CDC, WHO, IDSA, etc.), and input from clinical oncologists and infectious disease experts. ASCO will update this information as new questions emerge and evidence develops. |
|
Guideline - COVID-19 rapid guideline: delivery of systemic anticancer treatments - NICE (UK) The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic. |
|
Guideline - BGCS framework for care of patients with gynaecological cancer during the COVID-19 Pandemic - British Gynaecological Cancer Society The BGCS has produced this framework for the care of women with gynaecological cancer during the COVID 19 pandemic. The document was produced by a multidisciplinary team comprising gynaecological oncologists, clinical oncologists, medical oncologists and clinical nurse specialists. |
|
Article - Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance - MJA June 2020 Abstract: A pandemic coronavirus, termed SARS-CoV-2, causes a respiratory illness called COVID-19 disease, which is often severe or life-threatening. Patients with cancer may have compromised immunity due to their disease or its treatment, and early reports suggest cancer is a risk factor for severe COVID-19 disease. Community transmission of SARS-CoV-2 has the potential to overwhelm healthcare services, compromising the delivery of cancer investigations and care. Pending further evidence, this interim consensus guidance summarises the clinical presentation and diagnosis of COVID-19 disease, provides factors to consider when managing patients with cancer, and discusses risk factors for severe COVID-19 disease. Possible actions for clinicians managing patients with cancer are suggested, and are phased according to the presence or absence of community transmission and disruption to normal healthcare provision. Clinicians may need to reassess the risks and benefits of cancer therapies, balancing the risks of tumour progression against those of infections or other treatment complications on a case-by-case basis, while ensuring measures are proportionate, equitable and transparent. Key communication points for patients are proposed, and the potential impacts of COVID-19 disease on transfusion practice, stem cell transplantation and cellular therapies, radiation oncology, clinical trial participation and provision of palliative care are discussed. |
| Article - Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Internal Medicine Journal. June 2020 |